Upstream of KRAS, the epidermal growth factor receptor (EGFR) activation by its ligand binding (EGF) induces PD-L1 expression on NSCLC cells through the phosphatidylinositol 3-kinase-Protein kinase B-mammalian target of rapamycin (PI3K/Akt/mTOR) and the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathways [22]. Here, KRAS is linked to non-small cell lung carcinoma.